Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

This is an early-phase safety study testing a new cancer drug called ADU-1805 — which targets a protein that helps tumors hide from the immune system — in people with advanced solid tumors (cancers that have spread and are no longer responding to standard treatment). **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of an advanced or metastatic solid tumor cancer that is no longer responding to standard therapies, or for which no standard therapy exists - You are in generally good health (ECOG performance status 0 or 1) - For the expansion phase: you have colorectal cancer (MSS type without liver spread), endometrial cancer, kidney cancer, or non-small cell lung cancer that has progressed on immunotherapy **You may NOT be eligible if...** - You have melanoma, brain tumors (including glioblastoma), sarcoma, or pancreatic ductal cancer (dose escalation phase) - You are pregnant or breastfeeding - You have received more than 3 prior lines of treatment (expansion phase) - You have serious autoimmune disease or have recently received immunotherapy Talk to your doctor to see if this trial is right for you.